101 related articles for article (PubMed ID: 8029898)
1. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection.
Dalmasso AP; Platt JL
Transplant Proc; 1994 Jun; 26(3):1246-7. PubMed ID: 8029898
[No Abstract] [Full Text] [Related]
2. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor.
Dalmasso AP; Platt JL
Transplantation; 1993 Nov; 56(5):1171-6. PubMed ID: 8249120
[TBL] [Abstract][Full Text] [Related]
3. Activation of endothelial cells in hyperacute xenograft rejection.
Geller RL; Bach FH; Vercellotti GM; Nistler RS; Bolman RM; Fischel RJ; Leventhal J; Platt JL
Transplant Proc; 1992 Apr; 24(2):592. PubMed ID: 1566442
[No Abstract] [Full Text] [Related]
4. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells.
Laumonier T; Walpen AJ; Maurus CF; Mohacsi PJ; Matozan KM; Korchagina EY; Bovin NV; Vanhove B; Seebach JD; Rieben R
Transplantation; 2003 Sep; 76(5):838-43. PubMed ID: 14501864
[TBL] [Abstract][Full Text] [Related]
5. Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection.
Cable DG; Hisamochi K; Schaff HV
Circulation; 1997 Nov; 96(9 Suppl):II-58-63; discussion II-63-4. PubMed ID: 9386076
[TBL] [Abstract][Full Text] [Related]
6. Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation.
Saethre M; Lea T; Borgen MS; Fiane AE; Michaelsen TE; Thorsby E; Haraldsen G; Mollnes TE
Xenotransplantation; 2006 May; 13(3):215-23. PubMed ID: 16756564
[TBL] [Abstract][Full Text] [Related]
7. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection.
Heckl-Ostreicher B; Wosnik A; Kirschfink M
Transplantation; 1996 Dec; 62(11):1693-6. PubMed ID: 8970634
[TBL] [Abstract][Full Text] [Related]
8. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo- and xenoantibodies.
Poirier N; Blancho G
Transplant Proc; 2008 Mar; 40(2):581-3. PubMed ID: 18374134
[TBL] [Abstract][Full Text] [Related]
10. [Xenotransplantation: physiopathology of hyperacute and differentiated rejection, and therapeutic perspectives].
Malassagne B; Calmus Y; Houssin D; Weill B
Pathol Biol (Paris); 2000 May; 48(4):377-82. PubMed ID: 10868402
[TBL] [Abstract][Full Text] [Related]
11. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood.
Banz Y; Cung T; Korchagina EY; Bovin NV; Haeberli A; Rieben R
Xenotransplantation; 2005 Nov; 12(6):434-43. PubMed ID: 16202066
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanism of abnormal thromboregulation in xenograft rejection: loss of ecto-ATPases upon endothelial cell activation.
Robson SC; Candinas D; Siegel JB; Kopp C; Millan M; Hancock WW; Bach FH
Transplant Proc; 1996 Apr; 28(2):536. PubMed ID: 8623252
[No Abstract] [Full Text] [Related]
13. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival.
Stevens RB; Wang YL; Kaji H; Lloveras J; Dalmasso A; Bach FH; Rubinstein P; Sutherland DE; Platt JL
Transplant Proc; 1993 Feb; 25(1 Pt 1):382. PubMed ID: 8438344
[No Abstract] [Full Text] [Related]
14. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium.
Rieben R; Seebach JD
Trends Immunol; 2005 Jan; 26(1):2-5. PubMed ID: 15629401
[TBL] [Abstract][Full Text] [Related]
15. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
[TBL] [Abstract][Full Text] [Related]
16. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection.
Matsunami K; Miyagawa S; Yamada M; Yoshitatsu M; Shirakura R
Transplantation; 2000 Mar; 69(5):749-55. PubMed ID: 10755521
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation.
Anderson JB; Smith SA; van Wijk R; Chien S; Kotwal GJ
Transpl Immunol; 2003; 11(2):129-35. PubMed ID: 12799195
[TBL] [Abstract][Full Text] [Related]
18. Human serum-induced porcine endothelial cell apoptosis--another pathway to xenograft rejection.
Young DS; Kadokura M; Brockhausen I; Kashef V; Coles JG
Transplant Proc; 1996 Apr; 28(2):611-2. PubMed ID: 8623302
[No Abstract] [Full Text] [Related]
19. In vitro analysis of complement activation in xenogeneic hyperacute rejection.
Termignon JL; Calmus Y; Chéreau C; Kahan A; Houssin D; Weill B
Transplant Proc; 1992 Apr; 24(2):443-4. PubMed ID: 1566381
[No Abstract] [Full Text] [Related]
20. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin in the pig-to-human combination.
Gautreau C; Cardoso J; Woimant G; Zhao Z; Chereau C; Cherruau B; Vandeginste N; Devillier P; Houssin D
Transplant Proc; 1994 Jun; 26(3):1281. PubMed ID: 8029908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
